tafenoquine succinate

tafenoquine succinate (KRINTAFEL) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

KRINTAFEL is a marketed brand name for tafenoquine succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

tafenoquine succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.